The ‘Omics’ of Epigenetic Modulation by Valproic Acid Treatment in Traumatic Brain Injury—What We Know and What the Future Holds

Umar F. Bhatti, Aaron M. Williams, Patrick E. Georgoff, Hasan B. Alam*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

Traumatic brain injury (TBI) is a heterogeneous injury that is a major cause of morbidity and mortality worldwide. Epigenetic modulation through the alteration of cellular acetylation by valproic acid (VPA) administration has shown promise as a novel pharmacological treatment for TBI. It improves clinical outcomes through multiple mechanisms, many of which are still poorly understood. In recent years, omics technologies have emerged as a promising strategy to detect molecular changes at the cellular level. This review highlights the use of these high throughput technologies in advancing the understanding of epigenetic modulation by VPA in TBI. It also describes the future role of omics techniques in developing a point of care test to guide patient selection for VPA administration.

Original languageEnglish (US)
Article number1900068
JournalProteomics - Clinical Applications
Volume13
Issue number6
DOIs
StatePublished - Nov 1 2019
Externally publishedYes

Keywords

  • clinical trial
  • epigenetic modulation
  • omics
  • traumatic brain injury
  • valproic acid

ASJC Scopus subject areas

  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'The ‘Omics’ of Epigenetic Modulation by Valproic Acid Treatment in Traumatic Brain Injury—What We Know and What the Future Holds'. Together they form a unique fingerprint.

Cite this